Safety and efficacy of total colectomy with D3 lymph node dissection at colorectal cancer, developed at inflammatory bowel diseases (case control study)

Aim of investigation. To compare results of radical surgery in IBD-associated colorectal cancer (IBD-CRC) and sporadic colorectal cancer (spCRC) patients. Material and methods. The main group included retrospective cases of IBD-CRC with total colectomy and D3 lymph node (LN) dissection. The control group included matched cases of spCRC in 1:3 ratio according to localization and stage. Results. Overall 6 IBD-CRC and 18 spCRC patients were matched. IBD-CRC patients had longer operation time (313±37 vs 240±16 min, p=0.05), while there was no significant difference in mean volume of blood loss and postoperative stay duration (383±145 and 186±29 ml, p=0.24; 15.7±3.2 and 14.1±0.9 days, p=0.5 respectively). IBD-CRC patients spent longer time in ICU than spCRC (2.3±0.6 and 1.17±0.2 days, p=0.02) and had later bowel peristalsis restoration (2.0±0.4 and 1.3±0.1 days, p=0.02), however, time to first gas and stool discharge via stoma didn’t differ (2.5±1.4 and 2.1±0.6 days, p=0.5; 4.2±3.4 and 2.4±0.7 days, p=0.3). Tumor grade, histological type and adenoma rate didn’t differ between groups. Average number of involved LN in IBDCRC and spCRC was 39±16 and 30±5 (p=0.6). The rate of metastatic LN was 33.3% in both groups. The mean follow-up time was 27.3±5.3 months. Distant metastases were detected in 33.3% and 16.7% of IBD-CRC and spCRC cases respectively (p=0.4), without local recurrence in both groups. Conclusion. Tumor and LN characteristics in spCRC and IBD-CRC were similar, therefore radical surgery with extended LN dissection is recommended for IBDCRC patients.

неспецифические воспалительные заболевания кишечника, язвенный колит, болезнь Крона, колоректальный рак, расширенная лимфодиссекция

1. Rutter M.D., Saunders B.P., Wilkinson K.H., Rumbles S., Schofield G., Kamm M.A. et al. Thirtyyear analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130(4):1030-8.

2. Cheddani H., Dauchet L., Fumery M., Charpentier C., Marie Bouvier A., Dupas J.L. et al. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. Am J Gastroenterol 2016;111(10):1428-36.

3. Watanabe T., Konishi T., Kishimoto J., Kotake K., Muto T., Sugihara K. et al. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis 2011;17(3):802-8.

4. Gentilini L., Coscia M., Laureti S., Poggioli G. Surgery in presence of dysplasia in IBD. Ann Ital Chir 2011;82(1):37-40.

5. Japanese Classification of Colorectal Carcinoma. Japanese Research Society for Cancer of the Colon and Rectum. 2nd English edition ed. Tokyo: Kanehara & Co., Ltd; 2009.

6. Dindo D., Demartines N., Clavien P.A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240(2):205-13.

7. Edge S.B. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. xiv, 648 p.

8. Hohenberger W., Weber K., Matzel K., Papadopoulos T., Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation - technical notes and outcome. Colorectal Dis 2009;11(4):354-64; discussion 64-5.

9. Turnbull R.B. Jr. Cancer of the colon. The fiveand ten-year survival rates following resection utilizing the isolation technique. Ann R Coll Surg Engl 1970;46(5):24350.

10. Watanabe T., Muro K., Ajioka Y., Hashiguchi Y., Ito Y., Saito Y. et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 2017.

11. Bitton A., Buie D., Enns R., Feagan B.G., Jones J.L., Marshall J.K. et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012;107(2):179-94; author reply 95.

12. Златкина А.Р., Белоусова Е.А., Никулина И.В. Эпидемиологические аспекты воспалительных заболеваний кишечника в Московской области. Альманах клин мед 1999;2:41-50.

13. Reynolds I.S., O’Toole A., Deasy J., McNamara D.A., Burke J.P. A meta-analysis of the clinicopathological characteristics and survival outcomes of inflammatory bowel disease associated colorectal cancer. Int J Colorectal Dis 2017.

14. Renz B.W., Thasler W.E., Preissler G., Heide T., Khalil P.N., Mikhailov M. et al. Clinical outcome of IBD-associated versus sporadic colorectal cancer: a matched-pair analysis. J Gastrointest Surg 2013;17(5):98190.

15. Hrabe J.E., Byrn J.C., Button A.M., Zamba G.K., Kapadia M.R., Mezhir J.J. A matched case-control study of IBD-associated colorectal cancer: IBD portends worse outcome. J Surg Oncol 2014;109(2):117-21.

16. Stucchi A.F., Aarons C.B., Becker J.M. Surgical approaches to cancer in patients who have inflammatory bowel disease. Gastroenterol Clin N Am 2006;35(3):64173.

17. Chen S.L., Bilchik A.J. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 2006;244(4):602-10.

18. Rollven E., Abraham-Nordling M., Holm T., Blomqvist L. Assessment and diagnostic accuracy of lymph node status to predict stage III colon cancer using computed tomography. Cancer Imaging 2017;17(1):3.

19. Zhou L., Wang J.Z., Wang J.T., Wu Y.J., Chen H., Wang W.B. et al. Correlation analysis of MR/CT on colorectal cancer lymph node metastasis characteristics and prognosis. Eur Rev Med Pharmacol Sci 2017;21(6):121925.